This interplay between type I and type II PRMTs has recently been shown to have therapeutic value for cancer treatment and thus, it is not surprising that PRMT1 is synthetic lethal to PRMT5 deletion [24, 28, 29]. The gene discussed is PRMT1; the disease is cancer.